Combination treatment with atezolizumab plus bevacizumab improves progression-free survival

Results from the IMmotion150 phase II clinical trial showed that a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) improved progression-free survival (PFS) in patients with untreated metastatic renal cell carcinoma (mRCC) compared with standard treatment with sunitinib (Sutent). These results were presented at the 2017 European Society of Medical Oncology (ESMO) conference in Madrid, Spain […]

read more

Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer

A retrospective study conducted by researchers in the Czech Republic has analysed the outcomes of 219 people with metastatic renal cell carcinoma (mRCC) who received first-line treatment with vascular endothelial growth factor (VEGF) inhibitors, for example sunitinib, sorafenib, pazopanib, or bevacizumab, for at least 2 years. The vast majority of patients (166 patients, 75.8%) received […]

read more

Alternative scheduling of sunitinib and new treatment for kidney cancer: ASCO 2017 update

The following video from Practice Update is an interview with Dr Eric Jonasch, Professor at the Department of Genitourinary Medical Oncology in the Division of Cancer Medicine, and Director of the VHL Clinical Center at the University of Texas’ MD Anderson Cancer Center. Dr Jonasch is also a Board Director at the International Kidney Cancer […]

read more

Biomarkers predict kidney cancer treatment outcomes

Two recent studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago this week, suggest that levels of a protein called hepatocyte growth factor (HGF) in the blood, and certain changes (mutations) in the genes called BAP1 and PBRM1 in kidney cancer tumours are promising biomarkers for the prediction of survival […]

read more

Atezolizumab plus bevacizumab demonstrate encouraging results as first- or second-line treatment for advanced kidney cancer

The results of the IMmotion150 trial, a phase II trial looking at the effectiveness of atezolizumab plus bevacizumab combination as first- or second-line treatment for metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago yesterday. Three hundred and five (305) people with untreated metastatic RCC were […]

read more

Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer

In this video, Dr W. Marston Linehan, chief of the Urologic Oncology Branch of the National Cancer Institute in America, discusses the treatment of hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is very rare inherited condition, in which patients are at risk of developing non-cancerous (benign) tumours in the muscle under the skin (cutaneous leiomyomas), […]

read more

Promising clinical activities support combination immunotherapy for metastatic kidney cancer

The results of an open-label pilot study by researchers at The University of Texas MD Anderson Cancer Center in America comparing combinations of anti-PD1 (nivolumab) with either anti-CTLA-4 (ipilimumab) or anti-VEGF (bevacizumab) therapies, revealed “promising clinical activities” in people with metastatic renal cell carcinoma (mRCC). The results from the pilot study will be presented early […]

read more

Atezolizumab plus bevacizumab combination show promise for first-line kidney cancer treatment

Results from the IMmotion150 Phase 2 clinical trial, a global, multicentre, randomised study to compare the safety and effectiveness of atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) with atezolizumab alone and sunitinib (Sutent) alone, were presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando USA last week. The results showed […]

read more

VEGF/mTOR combination for non-clear cell kidney cancer

The combination of vascular endothelial growth factor (VEGF)-directed and mammalian target of rapamycin (mTOR)-directed therapies has not been very successful for the treatment of renal cell carcinoma (RCC). However, a recent study published in the Journal of Clinical Oncology has shown some success in non-clear cell RCC. Researchers combined the VEGF-directed drug, bevacizumab, with the […]

read more
Showing 21 to 29 of 29 results
  TOP